Managing paediatric musculoskeletal diseases with biological agents

The introduction of biological agents (BA) has markedly improved the outcome for children with musculoskeletal (MSK) diseases over the past two decades. Several BA have been developed, which alone or in combination with other immunomodulators, such as disease-modifying anti-rheumatic drugs (DMARD), have resulted in disease remission as an achievable target. Their use has also led to the reduction of reliance of steroid treatment and its undesirable side effects. The widest range of BA has been used for managing juvenile idiopathic arthritis (JIA), which is the most common rheumatic disease in childhood.
Source: Paediatrics and Child Health - Category: Pediatrics Authors: Tags: Symposium: Connective tissue and bone Source Type: research